Chinese Beijing Genome Institute, BGI, has announced that it has increased its collaboration with PentaBase, Denmark. Following a successful first benchmark of PentaBase’s technologies against competing technologies, BGI (together with Danish BGI partner SD Genomics) and PentaBase have now strengthened their collaboration with the aim to co-develop outstanding kits for the detection of important clinical biomarkers. The kits will be based on Real-Time PCR.
With the general trend pointing towards Personalized Medicine, development of robust, sensitive and specific genetic diagnostics is essential. BGI, SD Genomics and PentaBase want to launch a range of ground breaking diagnostic assays. It is a perfect fit between two parties with complementary knowledge and technology. "We have magnificent perspectives in creating a win-win situation,” says Ulf B. Christensen, CEO, PentaBase.